Latest data shows that almost one in three women around the globe have been subjected to intimate partner violence and/or nonpartner violence of a sexual nature at least once in their life. This estimate equals to roughly 30% of women or 736 million women worldwide, an alarming figure.
Now, a new study has determined that women who have suffered domestic abuse have a heightened risk of developing atopic illnesses. Common atopic diseases include asthma, atopic dermatitis and allergic rhinitis. The study, which was led by the University of Birmingham, reported its findings in the “Journal of Allergy and Clinical Immunology.”
For their research, the scientists analyzed patient records of an open cohort study in the United Kingdom, with a focus on adult women with a recorded exposure to domestic violence. They compared these to women without recorded exposure, excluding those who had been diagnosed with an atopic illness.
The researchers observed that there was a considerably larger percentage of women with both atopic illnesses and a history of being exposed to domestic abuse and violence in comparison to women who hadn’t.
In total, 13,852 women who had been exposed to domestic violence were compared to 49,036 women who hadn’t reported exposure, with the researchers observing a higher incidence of atopic disease in the former group. It should be noted that the researchers adjusted for potential confounders.
The corresponding author of the study, Dr. Joht Singh Chandan, stated that the group’s findings demonstrated that women with recorded exposure to domestic violence and abuse had a 52% higher risk of developing atopic illnesses. Chandan explained that domestic violence and abuse was a worldwide issue that disproportionately affected women, revealing that the group’s objective had been to better understand how domestic violence impacted overall health so that public health policies which were evidence-based could be developed to address domestic violence and abuse as well as its secondary effects.
The research had limitations, including the fact that data on their ethnicity lacked in the database and women in the exposed group were more likely to be current smokers in comparison to those in the unexposed group. Additionally, median follow-up for both groups was relatively short, especially given the nature of atopic ailments.
The researchers hope to address these limitations in future research.
Other researchers involved include Katrina Nash, MBChB; Nicholas Metheny, PhD; Sonica Minhas, MBBS; Julie Taylor, PhD; Krishna M. Gokhale, MSc; Siddhartha Bandyopadhyay, PhD; Caroline Bradbury-Jones, PhD; Nicola J. Adderley, PhD; and Krishnarajah Nirantharakumar, MD.
This study helps to highlight one of the factors that could be predisposing some women to atopic illnesses. Fortunately, a number of those atopic diseases can be managed easily by using readily available treatments from many companies such as Jupiter Wellness Inc. (NASDAQ: JUPW).
NOTE TO INVESTORS: The latest news and updates relating to Jupiter Wellness Inc. (NASDAQ: JUPW) are available in the company’s newsroom at https://ibn.fm/JUPW
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
